CN116407597A

CN116407597A - Xuan Bai pulse-activating decoction for resisting coronavirus and preparation method thereof

Info

Publication number: CN116407597A
Application number: CN202310305550.3A
Authority: CN
Inventors: 刘清泉; 徐霄龙; 张军; 姜慧; 宋麦芬; 徐佳; 杨思雯
Original assignee: Beijing Traditional Chinese Medicine Hospital
Current assignee: Beijing Traditional Chinese Medicine Hospital
Priority date: 2023-03-27
Filing date: 2023-03-27
Publication date: 2023-07-11
Anticipated expiration: 2043-03-27
Also published as: CN116407597B

Abstract

The invention provides a Xuan Bai pulse-activating decoction for resisting coronaviruses and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The Xuan Bai pulse-activating decoction for resisting coronavirus is prepared from Chinese medicinal raw materials such as radix glehniae, radix adenophorae, radix astragali, radix ophiopogonis, shizandra berry, fructus trichosanthis, gypsum, almond, raw rhubarb, pepperweed seed, verbena, raw liquorice and the like by decocting with water. The Xuan Bai pulse-activating decoction for resisting coronaviruses can effectively resist new coronaviruses, reduce the conversion rate of light and common patients, particularly reduce the death rate of heavy and critical new coronaries, and shorten the symptom recovery time and the hospitalization time of patients.

Description

Xuan Bai pulse-activating decoction for resisting coronavirus and preparation method thereof

Technical Field

The invention relates to the technical field of traditional Chinese medicines, in particular to a Xuan Bai pulse-activating decoction for resisting coronaviruses and a preparation method thereof.

Background

The novel coronavirus infection is a new acute infectious disease caused by the SARS-CoV-2 coronavirus of beta genus, which seriously threatens global health. The clinical manifestations of new coronavirus infection are influenza-like symptoms including fever, cough, weakness, etc., and some patients develop acute respiratory distress syndrome (Acute Respiratry Distress Syndrme, ARDS), even death.

Novel coronavirus infections are classified as light, common, heavy and dangerous. Along with the continuous variation of the new coronavirus strain, how to actively apply traditional Chinese medicine means to know and treat the new coronavirus infection and prevent and treat serious diseases, especially reduce the transformation rate and the death rate, becomes a new research hot spot.

The new coronavirus infection belongs to the category of epidemic disease in traditional Chinese medicine, the etiology is feeling epidemic disease, and the disease is treated by differentiation and diagnosis according to the conditions of illness state, syndrome and climate. The dialectical treatment of traditional Chinese medicine is characterized by "differentiation of symptoms and signs, and" combination of symptoms and signs ". Along with the continuous variation of virus strains and the different characteristics of the disease symptoms of patients in different regions and climates, the traditional Chinese medicine community has the knowledge and treatment of dynamic variation of pathogenic factors.

Currently, western medicine is still based on symptomatic and supportive treatment for the treatment of new coronavirus infections. Clinically, antiviral drugs such as adefovir, lopinavir/ritonavir and the like which are possibly effective are adopted, but a plurality of clinical researches prove the curative effect, and no drug capable of effectively resisting the novel coronavirus is found at present. Therefore, how to provide a pure traditional Chinese medicine formula capable of reducing the weight conversion rate of light and common patients, particularly capable of playing a role on heavy and critical patients, reducing the death rate of the heavy and critical patients and shortening the recovery time and the hospitalization time of the symptoms of the patients is a technical problem to be solved urgently at present.

Disclosure of Invention

In order to solve the problems, the invention provides a Xuan Bai pulse-activating decoction for resisting coronaviruses and a preparation method thereof. The Xuan Bai pulse-activating decoction for resisting coronaviruses can effectively resist new coronaviruses, can reduce the conversion rate of light and common patients, the death rate of patients with severe and critical diseases is reduced, the symptom recovery time and the hospitalization time of the patients are shortened, and the Xuan Bai pulse-activating decoction for resisting coronavirus comprises the following raw materials in parts by weight: 50-70 parts of radix glehniae, 50-70 parts of radix adenophorae, 50-70 parts of radix astragali, 20-40 parts of radix ophiopogonis, 10-20 parts of shizandra berry, 50-70 parts of fructus trichosanthis, 20-40 parts of gypsum, 10-20 parts of almond, 10-20 parts of raw rheum officinale, 20-40 parts of semen lepidii, 50-70 parts of verbena and 10-20 parts of raw liquorice.

Further, the Xuan Bai pulse-activating decoction for resisting coronaviruses comprises the following Chinese herbal medicines in parts by weight: 60 parts of radix glehniae, 60 parts of radix adenophorae, 60 parts of radix astragali, 30 parts of radix ophiopogonis, 10 parts of shizandra berry, 60 parts of fructus trichosanthis, 30 parts of gypsum, 15 parts of almond, 15 parts of raw rheum officinale, 30 parts of semen lepidii, 60 parts of verbena and 10 parts of raw liquorice.

The invention also provides a preparation method of the anti-coronavirus Xuan Bai pulse-activating decoction, which comprises the following specific steps: mixing radix Glehniae, radix Adenophorae, radix astragali, radix Ophiopogonis, fructus Schisandrae chinensis, fructus Trichosanthis, gypsum Fibrosum, semen Armeniacae amarum, radix et rhizoma Rhei, semen Lepidii, herba Verbenae, and Glycyrrhrizae radix at a certain proportion, decocting with 400 parts by weight of water, and filtering to obtain Xuan Bai SHENGMAI decoction for resisting coronavirus.

Further, the water decoction is performed by slow fire, and the water decoction time is 30min.

The application method of the Xuan Bai pulse-activating decoction for resisting coronaviruses comprises the following steps:

one dose is taken every day, and the medicine is taken for four times a day, and 7 days is a treatment course.

Further, the dose of Xuan Bai pulse-activating decoction for resisting coronavirus is 400mL.

Radix Glehniae, and radix Glehniae, which are dry roots of coralloides (Glehniae toralis Fr. Schmidtex Miq.) of Umbelliferae, is picked in summer and autumn, and is removed, and is cleaned, dried in the air, and is blanched in boiling water, and then is removed, dried, or cleaned and directly dried; sweet and slightly bitter in nature, slightly cold in taste, enters lung and stomach meridians, has the effects of nourishing yin and clearing lung-heat, tonifying stomach and promoting fluid production, and is used for treating cough due to lung heat and dryness, cough due to cough with phlegm and blood, and thirst due to heat and fluid consumption.

The radix Adenophorae product is dried root of Adenophora (Thunb.) or Adenophora (Adenophora trictaMiq.) of Campanulaceae, and is prepared by digging in spring and autumn, removing fibrous root, washing, scraping crude skin, cleaning, and drying; it has the actions of nourishing yin, clearing lung-heat, resolving phlegm and tonifying qi, and is suitable for cough due to lung heat, cough due to yin deficiency, dry cough, sticky phlegm, deficiency of qi and yin, dysphoria with smothery sensation and dry mouth, etc.

The radix astragali product is root of Astragalus mongholicus (Fisch.) bge. Var. Mongholicus (bge.) Hsiao or Astragalus membranaceus (A. Membrane.) bge. Of Astragalus of Leguminosae; sweet in taste and slightly warm in nature, enter spleen and lung meridians; has the effects of strengthening spleen and tonifying middle-jiao, invigorating yang and lifting and sinking, tonifying and strengthening the exterior, promoting urination, removing toxic substances and promoting granulation, and is mainly used for treating spleen qi deficiency, lung qi deficiency, qi deficiency and spontaneous perspiration, qi and blood deficiency, sores and ulcers which are difficult to collapse and difficult to decay, or which are difficult to heal for a long time.

The radix Ophiopogonis is dried root tuber of radix Ophiopogonis (Ophiopogon japonicus) of Liliaceae, has sweet taste, slightly bitter taste, slightly cold, and has effects of nourishing heart, lung, and stomach channel, nourishing yin, promoting salivation, moistening lung, and relieving cough: can be used for treating thirst, dry cough and hemoptysis due to deficiency of body fluid caused by deficiency of lung-yin and stomach-yin; palpitations due to deficiency of heart yin, and impairment of body fluids due to heat in the late stage of fever. With Sha Shen and Chuan Bei, it is indicated for dry cough due to lung yin deficiency.

The fructus Schisandrae is dry mature fruit of Schisandra chinensis (Turcz.) of Magnoliaceae, has sour and sweet taste, and is warm in nature, and has effects of astringing, invigorating qi, promoting fluid production, invigorating kidney, and calming heart, and can be used for treating chronic cough, asthmatic asthma, nocturnal emission, enuresis, frequent urination, chronic diarrhea, spontaneous perspiration, night sweat, body fluid consumption, thirst, internal heat, diabetes, palpitation, and insomnia.

The fructus Trichosanthis is fruit of Trichosanthes kirilowii Maxim of Cucurbitaceae, has cold nature, sweet taste, slightly bitter taste, has effects of clearing heat, eliminating phlegm, relieving chest stuffiness, and moistening intestine, and can be used for treating cough due to lung heat, turbid phlegm yellow and thick, chest pain, acute mastitis, pulmonary abscess, and swelling and pain due to intestinal abscess.

Gypsum is an ore containing calcium sulfate, has sweet and pungent taste, has strong cold property, enters lung and stomach meridians, and has the effects of clearing heat, purging fire, relieving restlessness and quenching thirst; calcining: has effects of healing sore, promoting granulation, eliminating dampness, stopping bleeding, etc., and can be used for treating exogenous febrile disease, high fever polydipsia, lung heat asthma and cough, stomach fire hyperactivity, headache, and toothache.

The almond is obtained by mixing kernel, apricot, semen Aristolochiae, and semen Armeniacae amarum, picking dry seed of bitter taste such as Rosaceae plant apricot or Aristolochia, removing pulp and core shell when the fruit is ripe in summer, collecting kernel, air drying, and drying in shade to prevent worm eaten; bitter taste, warm nature, entering lung and large intestine meridian, has the effects of eliminating phlegm, relieving cough, relieving asthma, moistening intestine and the like, and is mainly used for treating exogenous cough, asthma and fullness, pharyngitis and constipation due to intestinal dryness.

The radix et rhizoma Rhei Huang Benpin is root and rhizome of Rheum palmatum L, rheumatopsis tangutica Maxim, exBalf, or Rheum officinale L, and has effects of purging heat toxin, removing food stagnation, and removing blood stasis, and can be used for treating constipation due to excessive heat, delirium, food stagnation, early stage of dysentery, tenesmus, stagnation of the menstrual fluid, mass, epidemic febrile disease, acute eye pain, hematemesis, epistaxis, yang yellow, edema, stranguria, urine, carbuncle swelling toxin, furuncle, and fire injury.

The semen Lepidii product is seeds of Lepidium (Drabanemoranosa L.) of Lepidium of Brassicaceae, lepidium She (Lepidium virginicum mL.) and Lepidium webb.exPrantl of Lepidium, and has effects of purging lung, lowering qi, eliminating phlegm, relieving asthma, inducing diuresis, relieving edema, dispelling heat and eliminating evil, and is used for treating cough and excessive phlegm, pulmonary abscess, edema, hydrothorax, dysuria, chronic pulmonary heart disease, dyspnea of heart failure, carbuncle, malignant sore, scrofula, and tuberculosis.

The vervain also called horsewhip, iron vervain, bai Mabian, malaria vervain, phoenix-neck grass, purple top agrimony, verjingjingjing, has the effects of clearing heat and detoxicating, promoting blood circulation to remove blood stasis, inducing diuresis and relieving edema and the like, and is mainly used for treating exogenous fever, damp-heat jaundice, edema, dysentery, malaria, diphtheria, pharyngitis, gonorrhea, amenorrhea, abdominal mass, carbuncle swelling sore toxin and ulcerative gingivitis.

The raw Gan Caoben is dry root and rhizome of Glycyrrhiza uralensis Fisch. Of Leguminosae, glycyrrhiza glabra Bat. Or Glycyrrhiza glabra Licorice, and has effects of nourishing spleen, replenishing qi, clearing heat and toxic substances, eliminating phlegm, relieving cough, relieving pain, and harmonizing various drugs, and can be used for treating weakness of spleen and stomach, listlessness debilitation, palpitation, short breath, cough with excessive phlegm, gastric abdomen, limb spasm pain, carbuncle swelling sore, and toxicity, and relieving drug toxicity and intensity.

Compared with the prior art, the invention has the beneficial technical effects that:

the Xuan Bai pulse-activating decoction for resisting coronaviruses is prepared according to the compatibility principle of 'monarch, minister, assistant and guide' in proportioning, and based on dialectical legislation, the compatibility principle of the medicines such as mutual supplement and mutual opposite is utilized according to the pathogenesis of the diseases, so that the compatibility and combination of the medicines in the formula are tightly related to the pathogenesis of the diseases, the comprehensive effect of the medicines after compatibility is highly unified with that of the established treatment method, the new coronaviruses can be effectively resisted, the conversion rate of light and common patients can be reduced, the death rate of the patients with heavy and critical diseases can be reduced, and the symptom recovery time and the hospitalization time of the patients can be shortened.

Drawings

The invention is further described with reference to the following description of the drawings.

FIG. 1 is a comparison of Xuan white group and non-Xuan white group intercept times;

fig. 2 is a comparison of survival curves for the Xuanbai group and the non-Xuanbai group.

Detailed Description

The invention provides a Xuan Bai pulse-activating decoction for resisting coronaviruses, which comprises the following raw materials in parts by weight: 50-70 parts of radix glehniae, 50-70 parts of radix adenophorae, 50-70 parts of radix astragali, 20-40 parts of radix ophiopogonis, 10-20 parts of shizandra berry, 50-70 parts of fructus trichosanthis, 20-40 parts of gypsum, 10-20 parts of almond, 10-20 parts of raw rheum officinale, 20-40 parts of semen lepidii, 50-70 parts of verbena and 10-20 parts of raw liquorice.

In one embodiment, the anti-coronavirus Xuan Bai pulse-activating decoction comprises the following Chinese herbal medicines in parts by weight: 60 parts of radix glehniae, 60 parts of radix adenophorae, 60 parts of radix astragali, 30 parts of radix ophiopogonis, 10 parts of shizandra berry, 60 parts of fructus trichosanthis, 30 parts of gypsum, 15 parts of almond, 15 parts of raw rheum officinale, 30 parts of semen lepidii, 60 parts of verbena and 10 parts of raw liquorice.

In one embodiment, the water decoction is performed with slow fire for 30min.

In one embodiment, the anti-coronavirus Xuan Bai pulse-activating decoction is 400mL.

The technical scheme provided by the invention is further described below by combining with the embodiment.

Example 1

A preparation method of a Xuan Bai pulse-activating decoction for resisting coronavirus comprises the following steps:

60 parts of radix glehniae, 60 parts of radix adenophorae, 60 parts of radix astragali, 30 parts of dwarf lilyturf tuber, 10 parts of shizandra berry, 60 parts of snakegourd fruit, 30 parts of gypsum, 15 parts of almond, 15 parts of raw rhubarb, 30 parts of semen lepidii, 60 parts of verbena and 10 parts of raw liquorice are mixed according to a proportion, 400 parts of water is added for decocting, and then the mixture is filtered, so as to obtain the Xuan Bai pulse-activating soup for resisting coronavirus.

EXAMPLE 2 evaluation of clinical efficacy and safety

The invention adopts real world research and multi-center queue research design, collects patient medical record data and the like based on a hospitalization information system (collected from the hospitalization information system), comprises a severe coronavirus-caused pneumonia definite diagnosis patient collected by a plurality of hospitals in different areas such as a Beijing traditional Chinese medical hospital affiliated to a capital medical science university, a Shanghai public health clinical center, a Wuhan city traditional Chinese medical hospital, a Shenyang city, a Guangzhou city, an eighth people hospital and the like, and evaluates the clinical curative effect and safety of the Xuan Bai pulse-taking decoction for treating severe coronavirus infection.

1 subject of study

1.1 disease diagnostic criteria

Diagnosis of New coronavirus infection reference national Committee Wei Jian "New coronavirus diagnosis and treatment protocol (trial ninth edition) recently issued. Because the disease is a new sudden infectious disease, specific diagnosis standards slightly differ according to actual conditions, but basically are as follows:

1.1.1 confirmed cases

Suspected cases have one of the following etiologies or serological evidence:

(1) The novel coronavirus nucleic acid is detected positive;

(2) Novel coronans for non-vaccinated patients with novel coronavirus vaccines both virus-specific IgM antibodies and IgG antibodies were positive.

Clinical typing Standard

(1) Light weight.

The clinical symptoms are mild, and the symptoms are not manifested by pneumonia in imaging.

(2) And the common type.

The clinical manifestations and the visible pneumonia manifestations of the imaging.

(3) Heavy duty.

Adults are in compliance with any of the following:

(1) shortness of breath occurs, RR is more than or equal to 30 times/minute;

(2) in a resting state, the oxygen saturation degree is less than or equal to 93% when air is sucked;

(3) arterial blood oxygen partial pressure (PaO 2)/oxygen uptake concentration (FiO 2) less than or equal to 300mmHg (1 mmhg=0.133 kPa);

the high altitude (altitude above 1000 meters) area should be corrected according to the following formula PaO2/FiO 2:

PaO2/FiO2 x [ 760/atmosphere (mmHg) ].

(4) Clinical symptoms are progressively aggravated, and pulmonary imaging shows that lesions significantly progress >50% within 24-48 hours.

(4) Critical duty type

One of the following conditions is met:

(1) respiratory failure occurs and mechanical ventilation is required;

(2) shock occurs;

(3) ICU monitoring therapy is required to incorporate other organ failure.

Inclusion criteria

Patients with severe new coronavirus-induced pneumonia were diagnosed according to the national Wei Jian Committee for New coronavirus diagnosis and treatment protocol (trial ninth edition) [3 ].

Exclusion criteria

(1) Age less than 18 years old;

(2) The heavy type changes into dangerous type or death within 48 hours of admission;

(3) Other traditional Chinese medicine with similar composition to Xuan Bai pulse-activating decoction is used for treatment;

2 study group

According to the invention, the treatment actually accepted by a patient is grouped, the Xuan Bai pulse-activating decoction in the embodiment 1 is taken 400 milliliters, one dose is taken every day and is taken orally for four times, the standard treatment course is 7 days, the difference between the actual medicine use days of the patient and the standard treatment course in clinical practice is considered, the Xuan Bai pulse-activating decoction treatment is taken as an exposure factor, the Xuan Bai pulse-activating decoction treatment is used for more than or equal to 3 days in a cumulating way, the exposure group 1 is set together, and the control group 1 is:

(1) Exposure group: the accumulated usage of Xuan Bai pulse-activating decoction is more than or equal to 3 days.

(2) Control group: no treatment with Xuan Bai pulse-activating decoction was used, or a cumulative treatment with Xuan Bai pulse-activating decoction was used for <3 days.

3 observing index and observing time point

3.1 efficacy Observation index and Point of Observation

3.1.1 Main outcome index

The main outcome index is the rate and time of use of the ventilator (including nasal high flow oxygen inhalation, noninvasive ventilator or invasive ventilator), and the rate of mortality (death is defined as total cause death). And acquiring related information from the medical order record list and the course record of the hospitalization information system and judging.

3.1.2 Secondary outcome measures

(1) PSI rating and scoring: a pneumonia severity index (pneumonia severity index) rating and scoring;

the severity index rating and scoring of pneumonia is described in the national institute of advanced pneumonia clinical practice expert consensus (society of emergency physicians, national institute of advanced pneumonia clinical practice expert consensus [ J ]. Chinese emergency medicine, 2016, 36 (2): 97-107.).

(2) SOFA score: sequential organ failure (sequential organ failure assessment) score;

the sequential organ failure scores are described in the national institute of advanced pneumonia clinical practice expert consensus (national physician association, national institute of advanced pneumonia clinical practice expert consensus [ J ]. Chinese emergency medicine, 2016, 36 (2): 97-107.).

(3) Incidence of serious complications: complications refer to severe complications caused by pneumonia caused by new coronavirus infection, including acute respiratory distress syndrome, sepsis, acute kidney injury, acute myocardial injury, coagulation dysfunction and other organ failure;

(4) Number of hospitalization days;

(5) Number of days for survival;

(6) Auxiliary checking result: blood gas analysis: blood oxygen saturation, arterial oxygen partial pressure, arterial carbon dioxide partial pressure; serological examination: white blood cell count, percent neutrophil count, lymphocyte count, C-reactive protein, blood sedimentation, D-dimer, troponin I, troponin T, BNP; other inflammation indices: IL-1 beta, TNF-alpha; liver and kidney function index: creatinine, urea nitrogen, glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, etc.

(7) Multifactorial detection, microecology and metabonomics studies: and collecting part of clinical biological samples (throat swab, feces, blood and the like) in the diagnosis and treatment process of each unit, and analyzing the results.

3.1.3 safety Observation index and Observation time Point

The invention observes and evaluates the safety of Xuan Bai pulse-activating decoction, and extracts the following data information and other adverse reactions and side reactions according to the patient medical record:

(1) The digestive system: nausea, vomiting, abdominal pain, diarrhea, abdominal discomfort, and the like;

(2) Skin and accessories: rash, itching, etc.;

(3) The mental nervous system: dizziness, dysphoria, numbness of lips, numbness of limbs, headache, etc.;

(4) The respiratory system: chest distress, dyspnea, etc.;

(5) Cardiovascular system: palpitations, arrhythmias, and the like;

(6) Others.

4 statistical method

The continuity variables are expressed using x+ -s or median (P25, P75), and the differences between groups are measured using t-test or non-parametric test (Kruskal-WallisH test). Classification variables are expressed in terms of number of cases (percentages) and differences between groups are checked using chi-square. The linear regression model was used to analyze the effect of different factors on virus shedding to negative time. Survival analysis Cox regression models were used to analyze the effect of different factors on death outcome. The observed endpoint times were the following 3 events: (1) positive event: death within 30 days of follow-up; (2) a cutoff event: the patient loses visit or has a follow-up time of less than 30 days; (3) negative event: survival was followed for 30 days. Time to live days is the observation endpoint date minus the admission date. The severe group in the subgroup analysis was defined as patients with severe and critical clinical manifestations of covd-19. Sensitivity analysis stepwise variable corrections were performed in the regression model using the Enter method. The variable P <0.05 or clinically significant variable in the single factor analysis was included in the multifactor regression analysis correction. All data were statistically significant using a two-sided assay with a significance level of p=0.05, with P <0.05 as the difference. Statistical analysis was performed using graphpatrism 6.0 and stata16.0 software.

5 results

5.1 demographic information

In 212 new cases, men accounted for 60.4%, median age was 75 years, and aged 77.8% of aged 65 years and older. The number of smokers and drinkers in 212 cases was 13.7% and 7.1%, respectively. 72.6% of cases have chronic underlying diseases, hypertension, coronary heart disease, diabetes are the first three underlying diseases, and the proportions are 50.5%,24.5% and 21.2%, respectively. Xuan Bai treatment groups showed no statistical differences in the demographic characteristics of the two groups compared to the untreated group (Table 1).

TABLE 1.212 demographic information and history of chronic underlying disease in COVID-19 cases

Iqr=quartile spacing;

* Complications are not mutually exclusive, and some patients combine multiple underlying diseases, including tuberculosis, bronchiectasis, and the like.

5.2 cut-off time comparison

Median time from onset to diagnosis was the same for Xuan Baizu and unused group cases (7 days vs7 days, p=0.558, fig. 1A); however, the median time from onset to admission (9 days vs7 days, p=0.015, fig. 1B) was 2 days longer for Xuan Bai groups than for the unused group. In addition, group Xuan Bai had a median time to death from morbidity (14 days vs9 days, p=0.018, fig. 1C) that was 5 days longer than the unused group, and group Xuan Bai had a median time to death from hospitalization (6 days vs4 days, p=0.010, fig. 1D) that was 2 days longer than the unused group.

5.3 clinical manifestations, treatments and complications

Cough, fever and wheezing are the three most symptoms of this new crown case, the proportions of which are 64.6%,39.6% and 30.1%, respectively, and the clinical symptoms of Xuan Bai and non-Xuanbai groups have no significant difference (p > 0.05) (Table 2).

TABLE 2 clinical symptoms and signs in 212 cases of COVID-19

Of the 212 cases, 69.3% of cases appeared bilateral lesions, and the proportion of Xuan Baizu bilateral lesions was higher than that of the non-Xuan white group before administration, and the difference between the two groups was statistically significant (82.5% vs63.7%, p=0.004). In addition, 25.4% of Xuan Bai cases showed pleural effusions, with a non-Xuan Bai Zu pleural effusion ratio of 9.4%, and the difference between the two was statistically significant (p=0.004, table 3).

TABLE 3 imaging manifestations of 212 cases of COVID-19

The proportion of Xuan Baizu cases receiving antibiotic (88.9%), hormonal (69.8%) treatment was significantly higher than non-Xuan Baizu (75.2% and 52.3%), the differences were statistically significant (p < 0.05). Although the Xuanbai group and the non-Xuanbai group were not different in terms of receiving antiviral treatment, the proportion of the non-Xuanbai group using the alzvudine was significantly higher than Xuan Baizu (12.8% vs 1.6%), the difference was statistically significant (p=0.006, table 4). In addition, the virus shedding and negative conversion rate is higher (57.1% vs27.5%, p < 0.001) for the patients with the Xuan white, and the median survival time (16 days vs9 days, p < 0.001) is obviously longer than that of the patients without the Xuan white.

Table 4.212 clinical treatment analysis of cases of COVID-19

Complications occur in 75.9% of cases, and the proportion of complications occurring in the Xuanbai group is significantly higher than that of non-Xuan Baizu (90.4% vs69.5%, p=0.001). Overall, respiratory failure, hypoproteinemia, and acute kidney injury are the three complications that occur most frequently in this new case of wave crowns. Specifically, prior to administration, sepsis (15.8% vs4.0%, p=0.003), cardiac insufficiency (15.8% vs2.6%, p=0.001), electrolyte disorder (33.3% vs15.4%, p=0.003), hypoalbuminemia (49.2% vs25.5%, p=0.001), DIC (26.9% vs13.4%, p=0.017), secondary bacterial infection (11.1% vs2.0%, p=0.008) and the like occurred in a significantly higher proportion in the Xuan white group than in the non-Xuan white group, and the difference was statistically significant (table 5).

Table 5.212 cases of COVID-19 complication analysis

5.4 analysis of correlation between use or absence of Xuanbai and viral RNA shedding time

A total of 77 (36.3) patients reported a virus shedding to negative time, and the median time to virus shedding to negative was 9 (6-13) days (Table 4). The results of the one-factor linear regression analysis suggested (table 6) that in all patients, use Xuan Bai (β=2.95, p < 0.001) had a significant correlation with viral shedding time to negative compared to no use of rice white; use of Xuan Bai (β= -5.03, p=0.002) within 1-2 days after admission reduced viral shedding to negative time. In severe patients, use Xuan Bai (β=2.44, p=0.034) has a significant correlation with viral shedding time to negative compared to no use of alright; use of Xuan Bai (β= -5.03, p=0.013) within 1-2 days after admission reduced viral shedding to negative time.

TABLE 6 analysis of correlation between Xuanbai use and virus shedding time

Multi-factor linear regression analysis showed that model 1 was used to correct for demographic factors (age, sex) and Xuan Bai was used within 1-2 days after admission to reduce viral shedding to negative in all patients (β= -4.94, p=0.003) and critically ill patients (β= -5.16, p=0.014). Correction of demographic factors and chronic underlying disease using model 2 Xuan Bai used within 1-2 days after admission had a significant correlation with the reduction in viral shedding time to negative for all patients (β= -4.90, p=0.004) and critically ill patients (β= -5.18, p=0.015) (table 7).

TABLE 7 Multi-factor Linear regression analysis Xuanbai use correlation analysis with viral RNA shedding

Model 1: adjusting the age and sex;

model 22: can be used for treating age, sex, and chronic diseases.

5.5 comparison of survival curves

The hospitalization survival time was longer for Xuan Bai group cases than for the unused group cases, with higher survival rate (p=0.068; fig. 2A); this difference was more pronounced in the survival curves of severe cases (p=0.003; fig. 2B.) the survival rate of the Xuan white group cases was also higher than the unused group from admission to virus shedding time (p=0.021; fig. 2C), the survival curves of severe cases suggesting a greater difference in the survival rates of the two groups (p=0.001; fig. 2D)

5.6 cox regression analysis of time-to-live influencing factors

A total of 34 (19.1) patients died following 30 days of follow-up, and the median time to survival was 11 (7-15) days (table 4). The results of the single factor cox regression analysis suggested (table 8) that in all patients, use Xuan Bai (hr=0.51, p=0.101) had no significant correlation with time to live compared to no use of rice white; however, in severe patients, there was a significant correlation between the use Xuan Bai (hr=0.33, p=0.007) and the time to live compared to the non-use of albedo. Single factor cox regression (attached table 2) analyzes other factors that affect patient survival including: age (hr=1.05, p=0.010), wheezing (hr=2.08, p=0.057), double lung lesions (hr=0.37, p=0.009), mechanical ventilation (hr=0.08, p < 0.001). In the multifactorial cox regression analysis (table 9), the demographic factors (age, sex) were corrected using model 1, and Xuan Bai correlated with mortality risk in all patients (hr=0.43, p=0.050) and in critically ill patients (hr=0.31, p=0.006). Correction of demographics and combined disease using model 2, using Xuan Bai significantly reduced mortality risk in all patients (hr=0.38, p=0.030) and in critically ill patients (hr=0.23, p=0.001). The use of model 3 to correct for demographics, combined disease, clinical symptoms and chest imaging variables, xuan Bai was still associated with mortality risk in all patients (hr=0.44, p=0.075) and in critically ill patients (hr=0.28, p=0.007). Correction of demographic factors, combined disease, clinical symptoms, chest imaging, and clinical treatment variables using model 4, using Xuan Bai was an independent influencing factor in reducing the risk of mortality in all patients (hr=0.19, p=0.002) and in critically ill patients (hr=0.17, p=0.001).

For severe cases, mortality was significantly reduced with Xuanbai therapy, with an OR value of 0.33 and a 95% confidence interval of 0.15-0.74 (Table 8).

TABLE 8 Single factor analysis of Xuanbai use and death

TABLE 9 multiple factor regression analysis of Xuan Bai use and death

Model 1: adjusting the age and sex;

model 2: can be used for treating age, sex, and chronic diseases.

The principles and embodiments of the present invention have been described herein with reference to specific examples, the description of which is intended only to assist in understanding the methods of the present invention and the core ideas thereof; also, it is within the scope of the present invention to be modified by those of ordinary skill in the art in light of the present teachings. In view of the foregoing, this description should not be construed as limiting the invention.

Claims

1. An anti-coronavirus Xuan Bai pulse-activating decoction is characterized by comprising the following Chinese herbal medicines in parts by weight: 50-70 parts of radix glehniae, 50-70 parts of radix adenophorae, 50-70 parts of radix astragali, 20-40 parts of radix ophiopogonis, 10-20 parts of shizandra berry, 50-70 parts of fructus trichosanthis, 20-40 parts of gypsum, 10-20 parts of almond, 10-20 parts of raw rheum officinale, 20-40 parts of semen lepidii, 50-70 parts of verbena and 10-20 parts of raw liquorice.

2. The Xuan Bai pulse-activating decoction for resisting coronaviruses according to claim 1, which is characterized by comprising the following Chinese herbal medicines in parts by weight: 60 parts of radix glehniae, 60 parts of radix adenophorae, 60 parts of radix astragali, 30 parts of radix ophiopogonis, 10 parts of shizandra berry, 60 parts of fructus trichosanthis, 30 parts of gypsum, 15 parts of almond, 15 parts of raw rheum officinale, 30 parts of semen lepidii, 60 parts of verbena and 10 parts of raw liquorice.

3. The method for preparing the anti-coronavirus Xuan Bai pulse-activating decoction according to any one of claims 1 to 2, which is characterized by comprising the following steps: mixing radix Glehniae, radix Adenophorae, radix astragali, radix Ophiopogonis, fructus Schisandrae chinensis, fructus Trichosanthis, gypsum Fibrosum, semen Armeniacae amarum, radix et rhizoma Rhei, semen Lepidii, herba Verbenae, and Glycyrrhrizae radix at a certain proportion, decocting with 400 parts by weight of water, and filtering to obtain Xuan Bai SHENGMAI decoction for resisting coronavirus.

4. The method according to claim 3, wherein the water decoction is performed with slow fire for 30min.